A recent phase II study evaluated the use of bicalutamide, an androgen antagonist, in patients with AR+/ER- metastatic breast cancer, defining AR positivity as IHC >10%.24 Altogether 424 patients with ER-/PR- breast cancer were screened of which 12% were AR positive. The gene discussed is AR; the disease is breast carcinoma.